Truist Financial analyst Asthika Goonewardene maintained a Buy rating on Caribou Biosciences (CRBU – Research Report) today. The company’s shares closed yesterday at $5.02.
Goonewardene covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Compugen, and Mersana Therapeutics. According to TipRanks, Goonewardene has an average return of 8.1% and a 38.79% success rate on recommended stocks.
Caribou Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $23.60, implying a 370.12% upside from current levels. In a report released yesterday, Citi also maintained a Buy rating on the stock with a $30.00 price target.
See the top stocks recommended by analysts >>
Based on Caribou Biosciences’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $23.66 million and a GAAP net loss of $10 million. In comparison, last year the company earned a revenue of $3.3 million and had a GAAP net loss of $26.65 million
Based on the recent corporate insider activity of 8 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CRBU in relation to earlier this year. Last month, Steven Kanner, the CSO of CRBU bought 30,577.00 shares for a total of $82,252.13.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Caribou Biosciences (CRBU) Company Description:
Caribou Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies.
Read More on CRBU:
- Caribou Biosciences reports Q4 EPS (39c), consensus (37c)
- Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Precision BioSciences in non-exclusive patent license deal with Caribou
- Caribou Biosciences to Participate in Upcoming Investor Conferences
- Caribou Biosciences management to meet with Truist
